A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Mitomycin (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OLYMPUS
- Sponsors UroGen Pharma
- 21 May 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2019.
- 21 May 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Oct 2018.
- 03 Apr 2017 according to a UroGen Pharma media release, the company has obtained U.S. Orphan Drug Designation for MitoGel for the treatment of UTUC.